Quidel completes Ortho deal, emerges as QuidelOrtho

By LabPulse.com staff writers

May 27, 2022 -- Quidel announced on May 27 that it has completed its acquisition of Ortho Clinical Diagnostics. The combined diagnostic testing company will be known going forward as QuidelOrtho.

The new company is headquartered in San Diego and generated more than $3.5 billion in combined revenues in 2021, with approximately 6,000 employees. QuidelOrtho will trade on the Nasdaq Global Select Market under the symbol QDEL.

Under the terms of the agreement, former Ortho shareholders have received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. Former Quidel stockholders have received one share of QuidelOrtho common stock for each share of Quidel common stock.

The QuidelOrtho board is made up of eight former Quidel board members and four former Ortho board members.

Quidel shareholders approve $6B deal to buy Ortho
Quidel shareholders have approved the company's deal to buy Ortho Clinical Diagnostics. The acquisition is expected to close on May 27.
Quidel projects record Q1 for 2022
Quidel expects revenue increases for the first quarter of the 2022 fiscal year over the previous year, which the company is calling a record quarter.
Quidel reports full-year gains as Q4 sales slip
Diagnostic testing firm Quidel reported overall revenue growth for the company's full 2021 fiscal year, despite a decline in sales in the fourth quarter....
How will the Quidel, Ortho deal impact the point-of-care market?
A prediction that Quidel would buy Ortho Clinical Diagnostics a few years ago would have been greeted with incredulity, but COVID-19 has changed a lot...
Quidel inks deal to buy Ortho
Quidel has signed a definitive agreement to acquire Ortho Clinical Diagnostics for an equity value of approximately $6 billion.

Copyright © 2022 LabPulse.com

Last Updated bc 5/31/2022 6:14:49 AM